#Japan #Tokyo #Nankodo #MedSil AI #CollaboSquare

Enhancing Healthcare: NanKodo Partners with CollaboSquare for MedSil AI

In an innovative move to advance healthcare delivery, NanKodo Co., Ltd., headquartered in Bunkyo, Tokyo, has announced a strategic partnership with CollaboSquare Co., Ltd. This collaboration is focused on jointly developing and promoting a medical knowledge AI service known as MedSil AI.

Background and Objectives of the Partnership

The healthcare and caregiving sectors are inundated with vast amounts of information that demand swift and accurate collection and evaluation tailored to individual patient needs. In light of workforce shortages and evolving work styles, it has become increasingly critical to enhance the efficiency of information gathering across all medical professions. NanKodo aims to roll out MedSil AI, a highly reliable dialogue-based service tailored for healthcare professionals, to meet this pressing need.

CollaboSquare, on the other hand, operates a unique digital customer network housing over 450,000 healthcare workers through platforms like Collabo Portal and Medical Care Station (MCS). With its extensive reach across the Suzuken Group, CollaboSquare is well-equipped to facilitate the integration of MedSil AI into various medical and caregiving facilities nationwide.

This partnership will synergize the extensive medical information knowledge inherent in MedSil AI with the vast network of healthcare providers managed by Collabo ID and the capabilities of the Suzuken Group, including support for sales, billing, AI development, and more.

Overview of the Partnership

Both parties have defined specific roles in promoting the joint deployment of MedSil AI:

• - NanKodo:

- Focus on developing and enhancing the MedSil AI service.
- Expand content and services that cater to the diverse needs of various roles in the healthcare and caregiving sectors.

• - CollaboSquare:

- Utilize Collabo ID as the customer authentication backbone for MedSil AI, ensuring seamless access to services via Collabo Portal and MCS.
- Promote MedSil AI through various functionalities of the Suzuken Group, navigating its introduction and facilitating billing and recovery of payments.
- Provide ongoing support post-implementation to maintain service quality and gather valuable feedback for enhancement.

Future Outlook

Through this collaboration, the goal is to position MedSil AI as an indispensable knowledge resource for not just doctors but also pharmacists, nurses, and caregivers. By integrating NanKodo's medical content expertise with the established trust and digital integration points within the Suzuken Group, this initiative aims to enhance operational efficiency in healthcare settings. Ultimately, it seeks to improve the quality of team-based medical care through smarter technology.

About NanKodo

NanKodo is a forward-thinking publisher that specializes in medical, pharmaceutical, and nursing education resources. Since its inception, the company has contributed to medical advancement by supporting healthcare professionals and researchers through the publication of academic journals and specialized books. Beyond traditional publishing, NanKodo is keenly focused on the digital landscape, introducing AI-powered web services and electronic medical record systems, thus establishing a future-oriented perspective in delivering medical knowledge.

About CollaboSquare

As a member of the Suzuken Group, CollaboSquare is actively building and managing a healthcare platform that provides secure and accessible digital services tailored to healthcare professionals. Through the promotion of digital products and treatment support applications, CollaboSquare addresses the challenges facing healthcare institutions and drives digital transformation across the healthcare landscape.

In conclusion, the partnership between NanKodo and CollaboSquare is a transformative step towards innovating the healthcare industry, ensuring that healthcare professionals can access the best knowledge and practices efficiently and effectively.